title: Circulating anti-p53 antibodies in esophageal cancer patients.
abstract: Circulating anti-p53 protein antibodies (p53-Abs) have been detected in some cancer patients. The aim of the study was to determine the presence of circulating anti-p53 protein antibodies and their clinical significance in patients with esophageal carcinoma. Serum specimens from 75 consecutive patients with squamous cell carcinomas and 10 healthy subjects were studied. Enzyme linked immunosorbent assay (ELISA--Pharma Cell) was used to detect p53-Abs. At the time of diagnosis 20 (26.6%) of 75 analyzed patients had positive result in the p53-Abs test, but not any of the healthy subjects. The positive rate was 25% (1/4) cases in stage I, 41% (10/24) cases in stage IIA, 0% (0/8) cases in stage IIB, 28% (8/28) cases in stage III and 9% (1/11) cases in stage IV. In respect of tumour differentiation, cases graded as G1, G2 and G3 were positive in 28.5% (4/14), 25.9% (7/27) and 26.4% (9/34), respectively. There was no correlation between presence of p53-Abs and stage, rumour differentiation, lymph nodes metastases, tumour size, patient age and sex. In conclusion, the results of the present study indicate that serum p53-Abs did not correlate with cliniocopathologic feature of esophageal carcinoma.
authors.affiliation: Department of Thoracic Surgery, Medical Academy, Białystok, Poland. miroslaw@cksr.ac.bialystok.pl
authors.forename: M
authors.initials: M
authors.lastname: Kozłowski
authors.forename: O
authors.initials: O
authors.lastname: Kovalchuk
authors.forename: J
authors.initials: J
authors.lastname: Nikliński
authors.forename: L
authors.initials: L
authors.lastname: Chyczewski
authors.forename: E
authors.initials: E
authors.lastname: Starosławska
authors.forename: A
authors.initials: A
authors.lastname: Ciechański
authors.forename: A
authors.initials: A
authors.lastname: Dabrowski
authors.forename: W
authors.initials: W
authors.lastname: Niklińska
authors.forename: P
authors.initials: P
authors.lastname: Dziegielewski
authors.forename: G
authors.initials: G
authors.lastname: Lapuć
authors.forename: G
authors.initials: G
authors.lastname: Wallner
authors.forename: J
authors.initials: J
authors.lastname: Laudański
mesh_terms: D000328:Adult; D000368:Aged; D000912:Antibodies, Neoplasm / Q000097:blood*; D002294:Carcinoma, Squamous Cell / Q000276:immunology* / Q000556:secondary; D004938:Esophageal Neoplasms / Q000276:immunology* / Q000473:pathology; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D011237:Predictive Value of Tests; D016159:Tumor Suppressor Protein p53 / Q000276:immunology*
chemical_list: D000912:Antibodies, Neoplasm; D016159:Tumor Suppressor Protein p53